Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Psychosis; Acute Clear all

Conditions: Schizophrenia
Interventions: Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 34
States / cities: Birmingham, Alabama • Cerritos, California • Garden Grove, California + 26 more

Conditions: Psychosis, Anxiety, Depression, Behavioral and Psychiatric Symptoms of Dementia
Interventions: Behavioral Health Home Hospital; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Belmont, Massachusetts • Boston, Massachusetts • Jamaica Plain, Massachusetts

Conditions: Schizophrenia
Interventions: ALKS 9072, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 26
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 20 more

Conditions: Schizophrenia
Interventions: bitopertin [RO4917838], olanzapine, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 19
States / cities: Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Olanzapine, Metformin, Simvastatin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Butner, North Carolina • Durham, North Carolina

Conditions: Schizophrenia
Interventions: Placebo, Brexpiprazole, Quetiapine extended release; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Escondido, California

Conditions: Schizophrenia
Interventions: RBP-7000, Placebo, Risperidone; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 32
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 25 more

Conditions: Schizophrenia
Interventions: ALK3831, Olanzapine, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Culver City, California + 13 more

Conditions: Bipolar Disorder, Mood Disorders
Interventions: Placebo, Quetiapine, Paliperidone ER; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 22
States / cities: Cerritos, California • Garden Grove, California • Oceanside, California + 19 more

Conditions: Schizophrenia
Interventions: Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 39
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Carson, California + 30 more

Conditions: Schizophrenia
Interventions: Aripiprazole IM Depot, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 43
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 32 more

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Social Anxiety Disorder
Interventions: Fasedienol Nasal Spray - Placebo Nasal Spray, Fasedienol Nasal Spray - Fasedienol Nasal Spray, Placebo Nasal Spray - Placebo Nasal Spray; Drug
Lead sponsor: VistaGen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Sherman Oaks, California • Walnut Creek, California • Largo, Florida + 6 more

Conditions: Schizophrenia
Interventions: vabicaserin, risperidone, placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Little Rock, Arkansas • Cerritos, California • Escondido, California + 27 more

Conditions: Schizophrenia
Interventions: Placebo, ML-007C-MA BID, ML-007C-MA QD; Drug
Lead sponsor: MapLight Therapeutics; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 24
States / cities: Little Rock, Arkansas • Bellflower, California • Culver City, California + 21 more

Conditions: Affective Psychosis, Bipolar, Depression, Bipolar, Manic-Depressive Psychosis, Psychoses, Manic-Depressive
Interventions: Quetiapine fumarate (Seroquel) SR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 54
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more

Conditions: Schizophrenia
Interventions: LY2140023, Placebo; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: Schizophrenia
Interventions: N-Acetylcysteine, Placebo; Dietary Supplement · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: Placebo, Emraclidine 10 mg, Emraclidine 30 mg; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Little Rock, Arkansas • Anaheim, California • Garden Grove, California + 18 more

Conditions: Schizophrenia
Interventions: SEP-363856 75mg, SEP-363856 100mg, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 18
States / cities: Rogers, Arkansas • Anaheim, California • Bellflower, California + 15 more

Conditions: Schizophrenia
Interventions: TAK-063 20 mg, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Springdale, Alaska • Culver City, California • Lemon Grove, California + 12 more

Conditions: Psychotic Depression
Interventions: Aripiprazole; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Delirium, Agitated Behavior, Alcohol Withdrawl, Acute Confusional State, Acute Psychosis
Interventions: SOMA safe enclosure; Device
Lead sponsor: Griffin Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: risperidone, quetiapine; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 7
States / cities: San Diego, California • Hoffman Est, Illinois • Lake Charles, Louisiana + 4 more

Search by objective public record fields.

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care

A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

Cardio Risk of Acute Schizophrenia Olanzapine Duke

Brexpiprazole in Patients With Acute Schizophrenia

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

Long-term Study of Cariprazine in Patients With Schizophrenia

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.

A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder

Study Evaluating Vabicaserin in Subjects With Schizophrenia

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Phase III/Seroquel SR Bipolar Depression Monotherapy - US

A Study of LY2140023 in Patients With Schizophrenia

A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

Trial of Safety Nets In Hospitalized Patients

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder